Rábago-Monzón ÁR, Rodríguez-Rosas AM, Baldenebro-Félix DL, Camberos-Barraza J, Guadrón-Llanos AM, Ruíz-Ruelas VM, De la Herrán-Arita AK, MagañaGómez JA, Angulo-Rojo CE

Idioma: Español
Referencias bibliográficas: 40
Paginas: 171-181
Archivo PDF: 400.62 Kb.

RESUMEN

En los últimos años, las investigaciones en el campo de la neurociencia han revelado que enfermedades neurodegenerativas presentan una estrecha relación con el microbioma intestinal. Estudios clínicos y preclínicos, sugieren que el microbioma intestinal desempeña un papel crucial en el cerebro y revelan que un desequilibrio en su composición puede estar vinculado a enfermedades neurodegenerativas, cuyos mecanismos subyacentes aún requieren mayor estudio. Esta revisión tiene como objetivo destacar la relación entre el microbioma intestinal y las enfermedades neurodegenerativas, así como profundizar en la comprensión de su función y mecanismos relevantes. Además, se discuten las aplicaciones actuales y las perspectivas futuras de terapias relacionadas con el microbioma, las cuales, podrían abrir nuevas vías en la investigación de enfermedades neurodegenerativas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Zhang Y, Peng Y, Xia X. Autoimmune diseases and gut microbiota: a bibliometric andvisual analysis from 2004 to 2022. Clin ExpMed. 2023 Oct;23(6):2813-2827.

2. Wei M, Yang Z, Li S, Le W. Nanotherapeuticand Stem Cell Therapeutic Strategies inNeurodegenerative Diseases: A PromisingTherapeutic Approach. Int J Nanomedicine.2023 Feb 3;18:611-626.

3. Wang X, Liang Z, Wang S, Ma D, Zhu M,Feng J. Role of Gut Microbiota in MultipleSclerosis and Potential Therapeutic Implications. Curr Neuropharmacol.2022;20(7):1413-1426.

4. Conley MN, Wong CP, Duyck KM, Hord N,Ho E, Sharpton TJ. Aging and serum MCP1 are associated with gut microbiome composition in a murine model. PeerJ.2016;4:e1854.

5. Qiu P, Ishimoto T, Fu L, Zhang J, Zhang Z,Liu Y. The Gut Microbiota in InflammatoryBowel Disease. Front Cell Infect Microbiol.2022;12:733992.

6. Philip Mani A, Balasubramanian B, Mali LA,Joseph KS, Meyyazhagan A, PappuswamyM, Joseph BV. The Role of the Gut Microbiota in Neurodegenerative Diseases. Microbiol Res. 2024;15:489-507.

7. Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA. Ageing asa risk factor for neurodegenerative disease.Nat Rev Neurol. 2019;15(10):565-81.

8. Zheng Y, Bonfili L, Wei T, Eleuteri AM. Understanding the Gut–Brain Axis and Its Therapeutic Implications for NeurodegenerativeDisorders. Nutrients. 2023;15:4631.

9. Grasset E, Burcelin RJE. The gut microbiotato the brain axis in the metabolic control.Metab Disord. 2019;20(4):427-38.

10. Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek.2020;113(12):2019-2040.

11. Slota JA, Booth SA. MicroRNAs in Neuroinflammation: Implications in Disease Pathogenesis, Biomarker Discovery and Therapeutic Applications. Non-coding RNA.2019;5(2):35.

12. Sun P, Su L, Zhu H, Li X, Guo Y, Du X, et al.Gut Microbiota Regulation and Their Implication in the Development of Neurodegenerative Disease. Microorganisms.2021;9(11):2281.

13. Long JM, Holtzman DM. Alzheimer Disease:An Update on Pathobiology and TreatmentStrategies. Cell. 2019;179(2):312-39.

14. Chandra S, Jana M, Pahan K. Aspirin induces lysosomal biogenesis and attenuatesamyloid plaque pathology in a mouse modelof Alzheimer's disease via PPARα. Mol Neurobiol. 2023;60(24):595-7.

15. Tang JJ, Huang LF, Deng JL, Wang YM,Guo C, Peng XN, et al. Cognitive enhancement and neuroprotective effects of OABL, asesquiterpene lactone in 5xFAD Alzheimer'sdisease mice model.

16. Giau VV, Wu SY, Jamerlan A, An SSA, KimSY, Hulme J. Gut Microbiota and Their Neuroinflammatory Implications in Alzheimer'sDisease. Nutrients. 2018;10(11):1765.

17. Dash S, Syed YA, Khan MR. Understandingthe Role of the Gut Microbiome in Brain Development and Its Association With Neurodevelopmental Psychiatric Disorders. FrontCell Dev Biol. 2022;10:880544.

18. Warmbrunn MV, Herrema H, Aron-Wisnewsky J, Soeters MR, Van Raalte DH, Nieuwdorp M. Gut microbiota: a promising targetagainst cardiometabolic diseases. ExpertRev Endocrinol Metab. 2020;15(1):13-27.

19. Ferreiro A, Crook N, Gasparrini AJ, DantasG. The gut microbiome of healthy long-livedpeople. Sci Transl Med. 2023;15(510):abo2984.

20. Jemimah S, Praveenraj J, Sundarraj A, Srinivasan S. A comprehensive analysis of thegut microbiome in centenarians and youngadults. PLoS One. 2023;18(1):e0285346.

21. Goyal D, Ali SA, Singh RK. Emerging role ofgut microbiota in modulation of neuroinflammation and neurodegeneration with emphasis on Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry.2021;106:110112.

22. Zhang L, Wang Y, Xiayu X, Shi C, Chen W,Song N, et al. Altered gut microbiota in amouse model of Alzheimer’s disease. JAlzheimers Dis. 2017;60(4):1241-1257.

23. Varesi A, Campagnoli LIM, Fahmideh F,Pierella E, Romeo M, Ricevuti G, et al. TheInterplay between Gut Microbiota and Parkinson's Disease: Implications on Diagnosisand Treatment. Int J Mol Sci.2022;23(20):12289.

24. Vascellari S, Palmas V, Melis M, Pisanu S,Cusano R, Uva P, et al. Gut Microbiota andMetabolome Alterations Associated withParkinson’s Disease. mSystems.2020;5:e00561-20.

25. Li Z, Liang H, Hu Y, Lu L, Zheng C, Fan Y,et al. Gut bacterial profiles in Parkinson's disease: A systematic review. CNS NeurosciTher. 2023 Jan;29(1):140-157.

26. Scheperjans, F., Derkinderen, P., & Borghammer, P. (2018). The gut and Parkinson’s disease: hype or hope?. J Parkinson'sDis, 8(s1), S31-S39.

27. Heinzel S, Roeben B, Ben-Shlomo Y, LercheS, Alves G, Barone P, et al. Prodromal markers in Parkinson's disease: Limitations in longitudinal studies and lessons learned. AnnNeurol. 2021;89(5):939-49.

28. Schaeffer E, Kluge A, Böttner M, Zunke F,Cossais F, Berg D, et al. Alpha SynucleinConnects the Gut-Brain Axis in Parkinson'sDisease Patients - A View on Clinical Aspects, Cellular Pathology and AnalyticalMethodology. Front Cell Dev Biol.2020;8:573696.

29. Tan AH, Hor JW, Chong CW, Lim SY. Probiotics for Parkinson's disease: Current evidence and future directions. JGH Open.2021;5(4):414-419.

30. Araki T, editor. Amyotrophic Lateral Sclerosis. Brisbane (AU): Exon Publications; 2021.

31. Shin JW. Neuroprotective effects of melatonin in neurodegenerative and autoimmunecentral nervous system diseases. Encephalitis. 2023 Apr;3(2):44-53.

32. Sun J, Huang T, Debelius JW, Fang F. Gutmicrobiome and amyotrophic lateral sclerosis: A systematic review of current evidence.J Intern Med. 2021;290(4):758-788.

33. Sharifa M, Ghosh T, Daher OA, Bhusal P,Alaameri YA, Naz J, et al. Unraveling theGut-Brain Axis in Multiple Sclerosis: Exploring Dysbiosis, Oxidative Stress, and Therapeutic Insights. Cureus. 2023Oct;15(10):e47058.

34. Di Gioia D, Bozzi Cionci N, Baffoni L,Amoruso A, Pane M, Mogna L, et al. A prospective longitudinal study on the microbiotacomposition in amyotrophic lateral sclerosis.BMC Med. 2020;18:153.

35. Martin S, Battistini C, Sun J. A gut feeling inamyotrophic lateral sclerosis: microbiome ofmice and men. Front Cell Infect Microbiol.2022;12:839526.

36. Cox LM, Schafer MJ, Sohn J, Vincentini J,Weiner HL, Ginsberg SD, Blaser MJ. Calorierestriction slows age-related microbiotachanges in an Alzheimer's disease model infemale mice. Sci Rep. 2022;12(1):15842.

37. Xu Y, Liu X, Liu X, Chen D, Wang M, JiangX, et al. The roles of the gut microbiota andchronic low-grade inflammation in olderadults with frailty. Front Cell Infect Microbiol.2021;11:675414.

38. Mo X, Sun Y, Liang X, Li L, Hu S, Xu Z, et al.Insoluble yeast β-glucan attenuates high-fatdiet-induced obesity by regulating gut microbiota and its metabolites. Carbohydr Polym.2022;281:119046.

39. Shanahan F, Ghosh TS, O'Toole PW. TheHealthy Microbiome-What Is the Definition ofa Healthy Gut Microbiome? Gastroenterol.2021;160(2):483-494.

40. Singh R, Chandrashekharappa S, BodduluriSR, Baby BV, Hegde B, Kotla NG, et al. Enhancement of the gut barrier integrity by amicrobial metabolite through the Nrf2 pathway. Nat Commun. 2019;10(1):89.